Published in J Cell Biochem Suppl on January 01, 1996
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell (2013) 2.63
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol (2005) 1.44
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell (2016) 1.36
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
Novel human bronchial epithelial cell lines for cystic fibrosis research. Am J Physiol Lung Cell Mol Physiol (2008) 1.24
Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev (2015) 1.11
delta-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles. Mol Cancer (2009) 0.99
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest (2008) 0.96
Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics (2014) 0.84
The human lung adenocarcinoma cell line EKVX produces an infectious xenotropic murine leukemia virus. Viruses (2011) 0.79
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Med J (2015) 0.79
Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5. Mol Cancer Res (2015) 0.78
Discovery of novel types of inhibitors of S-adenosylmethionine synthesis by virtual screening. J Med Chem (2009) 0.77
Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer. PLoS One (2015) 0.76
Short-term exposure to tobacco toxins alters expression of multiple proliferation gene markers in primary human bronchial epithelial cell cultures. J Oncol (2011) 0.75
Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer (2017) 0.75
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Conservation of autosomal gene synteny groups in mouse and man. Nature (1978) 2.18
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07
Identification of mouse chromosomes required for murine leukemia virus replication. Cell (1977) 2.05
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 2.02
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1982) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
Gene mapping in Mus musculus by interspecific cell hybridization: assignment of the genes for tripeptidase-1 to chromosome 10, dipeptidase-2 to chromosome 18, acid phosphatase-1 to chromosome 12, and adenylate kinase-1 to chromosome 2. Cytogenet Cell Genet (1977) 1.98
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst (2000) 1.94
Disseminated intravascular coagulation (DIC): an approach. Am J Med (1972) 1.87
Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res (2001) 1.84
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med (1981) 1.84
Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene (1999) 1.83
Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst (1995) 1.83
Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci U S A (1981) 1.83
Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. Cancer Treat Rep (1979) 1.82
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
Antibodies in human sera reactive against an internal structural protein of human T-cell lymphoma virus. Nature (1981) 1.79
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene (1991) 1.79
Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res (1999) 1.78
Repeat polymorphisms within gene regions: phenotypic and evolutionary implications. Am J Hum Genet (2000) 1.75
Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. N Engl J Med (1981) 1.74
Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst (1993) 1.73
Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ (1994) 1.71
Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA (1995) 1.69
Computerized polymorphic marker identification: experimental validation and a predicted human polymorphism catalog. Proc Natl Acad Sci U S A (1998) 1.69
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res (1995) 1.67
Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A (2001) 1.67
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res (1997) 1.66
DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene (2008) 1.63
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet (1982) 1.61
Small cell carcinoma presenting as an extrapulmonary neoplasm: sites of origin and response to chemotherapy. J Natl Cancer Inst (1981) 1.59
Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene (1993) 1.59
Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem (2001) 1.58
CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer (1979) 1.57
Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer (2006) 1.56
LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res (2000) 1.56
Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res (1987) 1.53
DNA methylation profiles of lung tumors. Mol Cancer Ther (2001) 1.53
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res (2001) 1.52
Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res (2001) 1.51
Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res (1998) 1.51
Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst (1998) 1.50
Homologous genes for enolase, phosphogluconate dehydrogenase, phosphoglucomutase, and adenylate kinase are syntenic on mouse chromosome 4 and human chromosome 1p. Proc Natl Acad Sci U S A (1978) 1.48
Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A (1996) 1.48
Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta (1998) 1.48
5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res (2001) 1.46
Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res (2000) 1.45
Retracted DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer (2005) 1.45
Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med (1983) 1.44
L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol (1988) 1.43
myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest (1987) 1.43
Smoking abstinence and small cell lung cancer survival. An association. JAMA (1980) 1.43
Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst (1990) 1.42
Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res (1997) 1.41
Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol (1992) 1.41
Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res (2001) 1.40
Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest (1990) 1.38
Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene (1998) 1.38
Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer (1998) 1.38
High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol (2001) 1.36